A year ago Five Prime Therapeutics cut a fifth of its workforce to save money as its worked to advance its clinical-stage drugs for solid tumor cancers.
On Tuesday the company said one of those drugs, cabiralizumab, a Five Prime antibody that Bristol-Myers Squibb (NYSE: BMY) was testing in combination with its cancer immunotherapy nivolumab (Opdivo), failed to beat the standard of care in a Phase 2 trial in patients with pancreatic cancer.
Cabiralizumab blocks a protein called colony-stimulating factor-1 (CSF1R) in an effort to stymie the activation and survival of monocytes and macrophages. In preclinical tests in models of… Read more »
UNDERWRITERS AND PARTNERS
